1492 Capital Management’s Axsome Therapeutics AXSM Stock Holding History

1492 Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.17M	Buy	29,307 +10,713	+58%	+$2.32M	2.12%	14
2026 Q1	$3.14M	Buy	18,594 +531	+3%	+$91.7K	1.2%	33
2025 Q4	$3.3M	Hold	18,063	–	–	1.26%	34
2025 Q3	$2.19M	Buy	18,063 +6,220	+53%	+$701K	0.89%	46
2025 Q2	$1.24M	Buy	+11,843	New	+$1.25M	0.57%	63
2025 Q1	–	Sell	-11,385	Closed	-$963K	–	116
2024 Q4	$963K	Buy	+11,385	New	+$1.05M	0.46%	60

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

1492 Capital Management's AXSM Position: Q2 2026 in Review

1492 Capital Management increased its Axsome Therapeutics (AXSM) stake by 58% in Q2 2026, buying an estimated $2.32M and bringing the position to 29,307 shares worth $7.17M. The position accounts for 2.12% of the portfolio, ranked #14.

1492 Capital Management first reported a position in AXSM in Q4 2024 and has held it in 6 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

1492 Capital Management held 29,307 shares of Axsome Therapeutics worth $7.17M as of Q2 2026.
1492 Capital Management bought 10,713 Axsome Therapeutics shares in Q2 2026, an estimated $2.32M.
Axsome Therapeutics made up 2.12% of 1492 Capital Management's portfolio in Q2 2026, its #14 holding.
1492 Capital Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 6 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.